ArticleCureus2026
Ovarian Carcinosarcoma With Heterologous Chondrosarcomatous Differentiation: A Case Report and Review of Literature.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ovarian carcinosarcoma is a rare and aggressive malignancy characterized by the coexistence of epithelial and mesenchymal components. It poses considerable diagnostic and therapeutic difficulties largely due to its high propensity for peritoneal dissemination and unfavorable prognosis. We report the case of a 58-year-old woman presenting with progressive abdominal distension and pelvic pain. Imaging revealed a left ovarian mass associated with ascites and diffuse peritoneal carcinomatosis. Cytological analysis of ascitic fluid demonstrated malignant cells and histopathological examination of omental and peritoneal biopsies showed a biphasic tumor, composed of a high-grade serous carcinoma component and a heterologous chondrosarcomatous component. Immunohistochemistry revealed positivity for CK7, WT1, P16, and diffuse p53 expression, supporting a high-grade serous epithelial origin, while CK20 was negative. The diagnosis of ovarian carcinosarcoma with heterologous differentiation was retained. Given the advanced stage, the patient was considered for platinum-based chemotherapy. This case highlights the diagnostic challenges and histopathological features of ovarian carcinosarcoma. The current therapeutic regimen for carcinosarcoma is still based on tumor cytoreduction and platinum-containing chemotherapy; research on targeted therapy is still in progress.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.